Compositions and methods for reactivating latent viral infections
AssigneeThe Regents of the University of California
InventorsGuochun Jiang, Satya Dandekar
Life of this patent
Estimating the term…
Abstract
The present invention provides compositions comprising ingenol-3-angelate (PEP005) and one or more additional latency reactivation agents. The present invention also provides methods for reactivating a latent virus in a subject infected with the virus, the method comprising administering to the subject an effective amount of ingenol-3-angelate (PEP005) alone or in combination with one or more additional latency reactivation agents. In particular embodiments, the combination of compounds advantageously provides a synergistic effect at inducing reactivation of a latent virus such as HIV.
Claims9
A composition comprising ingenol-3-angelate (PEP005) and one or more additional latency reactivation agents, wherein PEP005 is present in an amount effective to synergistically enhance a therapeutic benefit of the one or more additional latency reactivation agents, wherein the therapeutic benefit comprises reactivation of a latent virus in a subject infected with the virus,
- wherein the one or more additional latency reactivation agents is a positive transcription elongation factor b activator, and
- wherein the virus is a human immunodeficiency virus (HIV).
A kit comprising:
- (a) ingenol-3-angelate (PEP005);
- and (b) one or more additional latency reactivation agents, wherein PEP005 is present in an amount effective to synergistically enhance a therapeutic benefit of the one or more additional latency reactivation agents, wherein the therapeutic benefit comprises reactivation of a latent virus in a subject infected with the virus,
- wherein the one or more additional latency reactivation agents is a positive transcription elongation factor h activator, and
- wherein the virus is a human immunodeficiency virus (HIV).
Dependencies are inferred from the claim text.